Risk-Benefit Balance of Renin-Angiotensin-Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia.
Shun KohsakaSuguru OkamiNaru MoritaToshitaka YajimaPublished in: Journal of clinical medicine (2022)
Treatment cessation/dose reduction of RAASis are common among HF patients. The risks of RAASi/MRA cessation may outweigh the benefits in patients with mild to moderate hyperkalemia.
Keyphrases
- heart failure
- end stage renal disease
- ejection fraction
- angiotensin ii
- chronic kidney disease
- newly diagnosed
- angiotensin converting enzyme
- prognostic factors
- acute heart failure
- atrial fibrillation
- computed tomography
- left ventricular
- magnetic resonance imaging
- contrast enhanced
- patient reported
- combination therapy
- smoking cessation